HuidaGene
is commercializing the LEAPER (Leveraging Endogenous ADAR for Programmable Editing of RNA) platform from Wei's PKU lab; LEAPER uses a single engineered ADAR-recruiting RNA (arRNA) to direct endogenous ADAR to a target adenosine, with no exogenous enzyme and therefore low immunogenicity and a small delivery payload.
- Country
- China
Research
arRNA editor (LEAPER)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| RNA editing (ADAR) therapeutics | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.